CBAY Shares Outstanding History
Below is a table of the CBAY shares outstanding history going back to 10/31/2013:

Date CBAY Shares Outstanding
10/31/20139.46M
3/3/201410.06M
4/30/201410.06M
6/18/201410.06M
7/31/201414.66M
10/31/201414.69M
3/1/201515.24M
4/30/201515.26M
8/7/201523.45M
11/2/201523.45M
3/1/201623.45M
4/30/201623.45M
7/31/201623.45M
10/31/201623.45M
3/1/201728.75M
4/30/201728.75M
8/3/201743.76M
10/31/201743.86M
2/28/201858.50M
4/30/201858.77M
7/31/201859.05M
10/31/201859.44M
1/31/201959.47M
4/30/201968.70M
7/31/201968.70M
10/31/201968.70M
2/29/202068.88M
4/30/202068.88M
7/31/202068.89M
10/31/202068.89M
2/28/202168.95M
4/30/202169.00M
7/31/202169.00M
10/31/202169.04M
2/28/202284.68M
4/30/202284.68M

Also see: CBAY Market Cap History
CBAY YTD Return
CBAY Historical Shares Outstanding:
+29.42% CAGR
CBAY Historical Shares Outstanding: +29.42% CAGR

Mouse over chart for data details
10/31/2013 ...4/30/2022
CymaBay Therapeutics is a clinical-stage biopharmaceutical company focused on developing and providing access to therapies for patients with liver and other chronic diseases. Co.'s pipeline includes the following clinical stage product candidates: seladelpar, a selective agonist for the peroxisome proliferator-activated receptor delta, which is a nuclear receptor that regulates genes involved in bile acid/sterol, lipid, and glucose metabolism, and regulation of certain inflammatory cells; and MBX-2982, which targets G protein-coupled receptor 119 (GPR119), a receptor that interacts with bioactive lipids known to stimulate glucose-dependent insulin secretion. We show 36 historical shares outstanding datapoints in our coverage of CBAY's shares outstanding history.

Understanding the changing numbers of CBAY shares outstanding — and comprehending the concept of differing number of shares outstanding in general comparing companies like CBAY versus peers — is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies. Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history. With this page we aim to empower investors researching CBAY by allowing them to research CBAY shares outstanding history as well as any other stock in our coverage universe.
Quotes delayed 20 minutes

Email EnvelopeFree CBAY Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Shares Outstanding Importance


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
CymaBay Therapeutics (CBAY) is categorized under the Healthcare sector; to help you further research historical shares outstanding numbers, below are some other companies in the same sector:

CBIO Shares Outstanding History
CBLI Shares Outstanding History
CBM Shares Outstanding History
CBMG Shares Outstanding History
CBPO Shares Outstanding History
CCCC Shares Outstanding History
CCEL Shares Outstanding History
CCRN Shares Outstanding History
CCXI Shares Outstanding History
CDAK Shares Outstanding History
More Healthcare companies »

 

CBAY Shares Outstanding History | www.SharesOutstandingHistory.com | Copyright © 2017 - 2022, All Rights Reserved

Nothing in SharesOutstandingHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.